# OPS-2071 Single and Multiple Dose Study to Investigate PK and PD Profile in Healthy Korean Male Subjects.

> **NCT01925521** · PHASE1 · COMPLETED · sponsor: **Korea Otsuka Pharmaceutical Co., Ltd.** · enrollment: 96 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Part1 : OPS-2071
- **DRUG:** Part1 : Placebo of OPS-2071
- **DRUG:** Part2 : OPS-2071
- **DRUG:** Part2 : Placebo of OPS-2071

## Key facts

- **NCT ID:** NCT01925521
- **Lead sponsor:** Korea Otsuka Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-08
- **Primary completion:** 2014-04
- **Final completion:** 2014-04
- **Target enrollment:** 96 (ACTUAL)
- **Last updated:** 2014-11-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01925521

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01925521, "OPS-2071 Single and Multiple Dose Study to Investigate PK and PD Profile in Healthy Korean Male Subjects.". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT01925521. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*